Bli medlem
Bli medlem

Du är här

2016-11-15

Vigmed: Interim report Vigmed Holding AB (publ) January - September 2016

Third quarter: 1 July - 30 September 2016

· Sales for the third quarter amounted to SEK 0.6 (1.0) million.
· Operating result in the third quarter amounted to SEK -6.3 (-9.0)
million.

· Cash flow from operating activities during the third quarter
amounted to SEK -13.0 (-6.7) million.

· On 30 September 2016 cash and cash equivalents amounted to SEK
24.8 (22.6) million.

First nine months: January-September 2016

· Sales for the interim period amounted to SEK 3.3 (3.0) million.
· Operating result for the interim period amounted to SEK -21.7
(-26.8) million.

· Cash flow from operating activities during the interim period
amounted to SEK -33.0 (-33.6) million.

· On 30 September 2016 cash and equivalents amounted to SEK 24.8
(22.6) million.

Significant events during the third quarter

Vigmed has continued to work closely with distributors to ensure the
success of ongoing and future tenders.

The ongoing work with the application for registration of Vigmed's
products in China, where the market for needlestick-protected
products is growing strongly, has accelerated during the quarter.

The Group's focus on cost reduction and cost control continues to
result in improved operating result and cash flow.

The ongoing discussion with the manufacturer of the SWiNG product
line, which has been considered an uncertainty factor for the Group,
was terminated in July 2016 after a common solution was reached. The
outcome regarding SWiNG Universal is in line with the assessment made
in the Annual Report for 2015. The agreement also included that
Vigmed acquires the packing equipment for manufacturing SWiNG Clic-on
and, on 31 December 2016 amortise the remaining debt for SWiNG
Clic-on tools and terminate co-operation with the contract
manufacturer.

For further information contact:
Chairman of the board, Sten Dahlborg +46 70 836 9419
CEO, Henrik Olsen +46 76 349 7364

Vigmed is a Swedish medical technology company whose mission is to
eliminate needlestick injuries and the associated risk of cross
infections with blood-borne infectious diseases by offering the
market unique needle-protected products. Vigmed is headquartered in
Helsingborg, Sweden. Vigmed's share is traded on NASDAQ OMX First
North in Stockholm (ticker VIG) and has approximately 5 600
shareholders. Remium Nordic AB is the Company's Certified Advisor.
Additional information about the company can be found on Vigmed's
website: www.vigmed.com/investor

-----------------------------------------------------------
http://news.cision.com/vigmed/r/interim-report-vigmed-holding-ab--publ--...
http://mb.cision.com/Main/5831/2123370/590204.pdf
http://mb.cision.com/Public/5831/2123370/a14d0cc6505f78f0.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.